LVW Advisors LLC Purchases Shares of 1,022 BeOne Medicines Ltd. - Sponsored ADR $ONC

Key Points

• LVW Advisors LLC has purchased 1,022 shares of BeOne Medicines Ltd., amounting to approximately $247,000, indicating growing institutional interest in the company during the second quarter.
• Insider selling has occurred recently, with a senior vice president selling 11,013 shares for over $3.3 million, highlighting potential concerns despite the company's recent earnings beat.
• BeOne Medicines holds a market cap of $35.74 billion, and despite a 0.8% decrease in stock price recently, analysts maintain a consensus rating of "Buy" with a target price around $336.30.

LVW Advisors LLC purchased a new stake in BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,022 shares of the company's stock, valued at approximately $247,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ONC. Parallel Advisors LLC purchased a new position in BeOne Medicines during the 2nd quarter worth approximately $59,000. Aaron Wealth Advisors LLC purchased a new position in shares of BeOne Medicines during the 2nd quarter valued at $200,000. Farther Finance Advisors LLC purchased a new position in shares of BeOne Medicines during the 2nd quarter valued at $39,000. Avanza Fonder AB purchased a new position in shares of BeOne Medicines during the 2nd quarter valued at $199,000. Finally, Public Employees Retirement System of Ohio purchased a new position in shares of BeOne Medicines during the 2nd quarter valued at $3,491,000. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at BeOne Medicines

In related news, SVP Chan Henry Lee sold 11,013 shares of the stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $300.45, for a total value of $3,308,855.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Corazon (Corsee) D. Sanders sold 2,665 shares of the stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $337.00, for a total transaction of $898,105.00. The disclosure for this sale can be found here. Insiders have sold 181,315 shares of company stock valued at $54,839,498 in the last three months. Company insiders own 6.62% of the company's stock.

BeOne Medicines Stock Down 0.8%

BeOne Medicines stock opened at $326.06 on Monday. The firm has a fifty day moving average price of $314.02 and a two-hundred day moving average price of $271.21. The firm has a market cap of $35.74 billion, a price-to-earnings ratio of -188.47 and a beta of 0.21. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.95 and a quick ratio of 1.72. BeOne Medicines Ltd. - Sponsored ADR has a fifty-two week low of $170.99 and a fifty-two week high of $351.27.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $0.84 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.36. The business had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.24 billion. BeOne Medicines had a negative net margin of 3.89% and a negative return on equity of 1.22%. As a group, analysts forecast that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ONC. Barclays began coverage on shares of BeOne Medicines in a report on Thursday, September 18th. They set an "overweight" rating and a $385.00 price target on the stock. JPMorgan Chase & Co. lifted their price objective on shares of BeOne Medicines from $321.00 to $345.00 and gave the company an "overweight" rating in a research note on Thursday, July 17th. Guggenheim lifted their price objective on shares of BeOne Medicines from $350.00 to $365.00 and gave the company a "buy" rating in a research note on Thursday, August 7th. Royal Bank Of Canada lifted their price objective on shares of BeOne Medicines from $349.00 to $364.00 and gave the company an "outperform" rating in a research note on Thursday, August 7th. Finally, Zacks Research raised shares of BeOne Medicines from a "hold" rating to a "strong-buy" rating in a research note on Thursday, September 18th. One research analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $336.30.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.